



ISSN NO. 2320-5407

ISSN(O): 2320-5407 | ISSN(P): 3107-4928

International Journal of Advanced Research

Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

REVIEWER'S REPORT

Manuscript No.: IJAR-57195

Title: The Evolving Landscape of Multiple Myeloma.

Recommendation:

Accept as it is

Accept after minor revision...

Accept after major revision

Do not accept (*Reasons below*)

Rating	Excel.	Good	Fair	Poor
Originality		Good		
Techn. Quality		Good		
Clarity		Good		
Significance	Excellent			

Reviewer's ID: Dr. Sumathi

Detailed Reviewer's Report

- The landscape of multiple myeloma (MM) is evolving from a fatal diagnosis to a manageable chronic disease through highly personalized quadruplet therapies, CAR-T cell therapies, and bispecific antibodies. Key trends include early, aggressive treatment for newly diagnosed patients (NDMM) and a focus on deep remission using MRD (minimal residual disease) monitoring, increasing median survival to 8–10 years.**
- As multiple myeloma progresses, abnormal plasma cells accumulate in the bone marrow, causing increased CRAB features: elevated Calcium, Renal (kidney) failure, Anemia, and Bone lesions. The disease becomes more aggressive, leading to severe fatigue, pain, infections, and reduced treatment responses.**
- In multiple myeloma, cancerous plasma cells build up in bone marrow. The bone marrow is the soft matter inside bones where blood cells are made. In the bone marrow, the cancer cells crowd out healthy blood cells. Rather than make helpful antibodies, the cancer cells make proteins that don't work right.**

REVIEWER'S REPORT

- 4. Multiple myeloma is staged using the Revised International Staging System (R-ISS) into three main stages—I, II, and III—based on blood tests (B2M, Albumin, LDH) and genetics. These stages measure the severity of the cancer, ranging from less aggressive (Stage I) to highly advanced (Stage III).**
- 5. Long considered one of the most deadly and incurable cancers, multiple myeloma is now being viewed by more and more oncologists as an eminently treatable disease based on exciting new immunotherapies, including CAR T cell therapy and bispecific antibodies.**
- 6. The exact cause of multiple myeloma is not known and no avoidable risk factors have been found. However, certain things appear to make you more likely to develop the disease. Gender: Men are slightly more likely to develop myeloma. Race: Black people are twice as likely to develop myeloma than white people.**
- 7. Multiple myeloma is a rare, generally incurable blood cancer that begins in the bone marrow, where cancerous plasma cells overproduce abnormal antibodies (M proteins). These cells crowd out healthy blood cells and destroy bone, leading to pain, infections, kidney damage, and fatigue. While incurable, it is highly treatable, often managed for years with therapies like chemotherapy, steroids, and targeted treatments.**
- 8. The first signs of multiple myeloma are often vague, with persistent bone pain (especially in the back or ribs) and unexplained, worsening fatigue (due to anemia) being the most common early indicators. Other initial signs, often found through routine blood tests, include high calcium levels, kidney issues, or frequent infections.**
- 9. Key words and abstract must be given.**
- 10. And only theoretical part is given there is no such a result and discussion part to publish the papers.**
- 11. Summary points also be added.**
- 12. After those changes can be published.**